LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Response to Tenofovir Among Lamivudine-Experienced Hepatitis B and HIV Coinfected Adolescents

Publication

Author(s):

Aurpibul L1, Lumbiganon P, Hansudewechakul R, Kanjanavanit S, Bunupuradah T, Kosalaraksa P, Taeprasert P, Puthanakit T

Pub Title:

Response to Tenofovir Among Lamivudine-Experienced Hepatitis B and HIV Coinfected Adolescents

Pub Date:

Dec 21 2016

Pub Region(s):

Asia-Pacific

Journal:

Title: 
Pediatr Infect Dis J

PubMed: 28005687
Pub PDF:

We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-HIV coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC-exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although HBsAg loss or HBeAb seroconversion did not occur.

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Pediatr Infect Dis J. 2016 Dec 21. doi: 10.1097/INF.0000000000001491. [Epub ahead of print] Response to Tenofovir Among Lamivudine-Experienced Hepatitis B and HIV Coinfected Adolescents. Aurpibul L1, Lumbiganon P, Hansudewechakul R, Kanjanavanit S, Bunupuradah T, Kosalaraksa P, Taeprasert P, Puthanakit T.